Conformational epitopes in respiratory syncytial virus g protein central conserved region
AssigneesTrellis Bioscience, LLC, The Regents of the University of California
InventorsRebecca DUBOIS, Stas FEDECHKIN, Lawrence M. KAUVAR
Life of this patent
Estimating the term…
Abstract
X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.
Claims10
A method to exert a prophylactic or therapeutic effect against RSV infection in a subject which method comprises administering to a subject in need of such effect an effective amount of a pharmaceutical or veterinary composition or vaccine comprising a mutant or peptidomimetic of a peptide having the amino acid sequence of residues 161-197 of respiratory syncytial virus (RSV) G protein (SEQ ID NO:1) or of positions 169-198 (SEQ ID NO:3), or of positions 157-197 (SEQ ID NO:4), or of positions 148-197 (SEQ ID NO:5), or of positions 161-195 (SEQ ID NO:6) that has diminished activity with respect to activating the chemokine receptor responsive to fractalkine as compared to the respective peptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6;
- and
- which binds mAb 3D3, and/or 2D10 and/or 3G12;
- and/or
- which elicits antibodies immunoreactive with RSV G protein,
- wherein the mutant or peptidomimetic elicits sub-nM affinity antibodies immunoreactive with an epitope of RSV G protein conserved between A and B strains of the virus.
A method to exert a prophylactic or therapeutic effect in a subject, which method comprises administering to a subject in need of such effect an effective amount of a pharmaceutical or veterinary composition or vaccine, the pharmaceutical or veterinary composition or vaccine comprising, as an active agent, a mutant or peptidomimetic of peptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6 that stimulates or inhibits the chemokine receptor responsive to fractalkine as compared to the respective peptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6.
A binding moiety that has the characteristics of strain independent high affinity for the conserved region of the RSV G protein and neutralizing activity identified by a method that comprises contacting a candidate binding moiety with a conformationally restrained form of a peptide having the shape as shown in FIGS. 2A, 2B or 2C or a peptidomimetic thereof and detecting the presence or absence of a complex between said candidate binding moiety and said shaped peptide or peptidomimetic, wherein the presence of said complex that shows a binding affinity of the candidate binding moiety for said peptide or peptidomimetic at least as strong as 100 pM identifies said binding moiety as having said characteristics, wherein the candidate binding moiety is an aptamer or a member of a combinatorial library of alternative scaffolds or is an antibody or fragment thereof.
A peptide having the amino acid sequence of residues 161-197 of respiratory syncytial virus (RSV) G protein (SEQ ID NO:1) or the amino acid sequence of positions 162-172 (SEQ ID NO:2) or of positions 169-198 (SEQ ID NO:3), or of positions 157-197 (SEQ ID NO:4), or of positions 148-197 (SEQ ID NO:5), or of positions 161-195 (SEQ ID NO:6), each chemically stabilized to retain the conformation exhibited upon binding to antibody;
- or
- a mutant or peptidomimetic of any of the peptides of SEQ ID NOs:1-6 that has enhanced immunogenicity as compared to the respective peptide of or that has reduced immunogenicity as compared to the respective peptide of any of SEQ ID NOs:1-6.
Dependencies are inferred from the claim text.